GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (STU:BO1) » Definitions » Cyclically Adjusted Price-to-FCF

BioCryst Pharmaceuticals (STU:BO1) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCryst Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioCryst Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BioCryst Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.119/134.9266*134.9266
=-0.119

Current CPI (Mar. 2025) = 134.9266.

BioCryst Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.206 100.684 0.276
201509 -0.156 100.392 -0.210
201512 -0.236 99.792 -0.319
201603 -0.270 100.470 -0.363
201606 -0.157 101.688 -0.208
201609 -0.214 101.861 -0.283
201612 -0.075 101.863 -0.099
201703 -0.106 102.862 -0.139
201706 -0.107 103.349 -0.140
201709 -0.127 104.136 -0.165
201712 -0.091 104.011 -0.118
201803 -0.162 105.290 -0.208
201806 -0.122 106.317 -0.155
201809 -0.285 106.507 -0.361
201812 -0.193 105.998 -0.246
201903 -0.218 107.251 -0.274
201906 -0.197 108.070 -0.246
201909 -0.228 108.329 -0.284
201912 -0.072 108.420 -0.090
202003 -0.137 108.902 -0.170
202006 -0.171 108.767 -0.212
202009 -0.185 109.815 -0.227
202012 -0.199 109.897 -0.244
202103 -0.289 111.754 -0.349
202106 -0.122 114.631 -0.144
202109 -0.112 115.734 -0.131
202112 -0.163 117.630 -0.187
202203 -0.384 121.301 -0.427
202206 -0.143 125.017 -0.154
202209 -0.177 125.227 -0.191
202212 -0.123 125.222 -0.133
202303 -0.236 127.348 -0.250
202306 -0.094 128.729 -0.099
202309 -0.103 129.860 -0.107
202312 -0.043 129.419 -0.045
202403 -0.241 131.776 -0.247
202406 -0.007 132.554 -0.007
202409 0.036 133.029 0.037
202412 -0.027 133.157 -0.027
202503 -0.119 134.927 -0.119

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCryst Pharmaceuticals  (STU:BO1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals Headlines

No Headlines